Biogen's Alzheimer's Treatment Gets Negative CHMP Opinion
18 December 2021 - 12:00AM
Dow Jones News
By Chris Wack
Biogen Inc. and Eisai Co. Ltd. said Friday that the Committee
for Medicinal Products for Human Use of the European Medicines
Agency has adopted a negative opinion on the Marketing
Authorization Application for aducanumab.
Aducanumab is intended to be used for the treatment of the early
stages of Alzheimer's disease known as mild cognitive impairment
due to Alzheimer's disease and mild Alzheimer's disease
dementia.
This decision is aligned to the negative trend vote of the
committee in November. Biogen said it would seek a re-examination
of the opinion by the CHMP.
The European Commission's regulations allow an applicant to
request a re-examination of a CHMP opinion, followed by submission
of documentation with detailed grounds for the request. The
committee has 60 days after receipt of this documentation to
re-examine their opinion.
The MAA included efficacy, safety and biomarker data from a
global, multistudy clinical development program which included
3,600 patients in more than 20 countries.
In June, the U.S. Food and Drug Administration granted
accelerated approval for Aduhelm aducanumab-avwa 100 mg/mL
injection for intravenous use as the first Alzheimer's disease
treatment to address a defining pathology of the disease by
reducing amyloid beta plaques in the brain. Aduhelm is also
approved in the United Arab Emirates.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 17, 2021 07:45 ET (12:45 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Eisai (PK) (USOTC:ESALY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Eisai (PK) (USOTC:ESALY)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Eisai Company Ltd (PK) (OTCMarkets): 0 recent articles
More Eisai Company Ltd (PK) News Articles